So-Young to Report Fourth Quarter and Full Year 2022 Financial Results on March 21, 2023
BEIJING, March 14, 2023 /PRNewswire/ -- So-Young International Inc. (NASDAQ: SY) ("So-Young" or the "Company"), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2022, before U.S. markets...
Patient Enrollment Completed for Phase III Clinical Trial of Akeso’s Cadonilimab in Treatment of Gastric Cancer
HONG KONG, March 14, 2023 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that patient enrollment has been completed for its pivotal Phase III clinical trial for cadonilimab (PD-1/CTLA-4 bi-specific antibody, AK104), the world's first approved and marketed dual-immune checkpoint bi-specific antibody drug, for use in combination with chemotherapy as first-line therapy for advanced...
OSANO Debuts Latest Products at COSMOPROF 2023
BOLOGNA, Italy, March 14, 2023 /PRNewswire/ -- COSMOPROF WORLDWIDE BOLOGNA, one of the most influential global events dedicated to all facets of the beauty industry, is taking place from the 17th to 20th, March, 2023. OSANO launched a series of top-notch products, including Beauty Equipment, Body Shaping Machine, Facial Care Machine, Ultrasound Cavitation Device, Lipo Laser Instrument, Hair Removal Machine,...
DeepCare debuts at IDS Cologne 2023
COLOGNE, Germany, March 14, 2023 /PRNewswire/ -- DeepCare, a leading AI solution provider for dental care, debuts its latest innovative products at the International Dental Show (IDS) in Cologne, Germany, from March 14th to 18th, 2023. IDS is the world's largest and most influential dental exhibition, attracting over 2,000 exhibitors from 65 countries and 160,000 visitors worldwide, and this...
Antengene Announces IND Approval for the Phase I CLINCH Trial of ATG-022 (Claudin 18.2 ADC) for the Treatment of Advanced or Metastatic Solid Tumors in China
- Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate (ADC) targeting the Tumor Associated Antigen (TAA) Claudin 18.2. - The Phase I CLINCH trial is designed to evaluate the safety, pharmacology, and preliminary efficacy of ATG-022 monotherapy in patients with advanced or metastatic solid tumors. ATG-022 has also received...
BEYOND Expo Back in Macao for 2023 to See “Technology Redefined” in one of Asia’s Biggest Tech Events
MACAO, March 14, 2023 /PRNewswire/ -- Now on its third edition, BEYOND International Technology Innovation Expo (BEYOND Expo) returns to its real-world conference format in Macao from May 10 to 12, 2023. The live-streamed and in-person conference format will provide exhibitors and attendees with more direct access to media channels and networking opportunities than ever before through the largest...
Qritive and Corista Announce Partnership to Advance the Use of Computational Digital Pathology Workflows with Integrated Image Management
SINGAPORE, March 14, 2023 /PRNewswire/ -- Qritive, a leading developer of artificial intelligence (AI)-powered cancer diagnostics, and, Corista, a leading provider of clinical, research and educational digital pathology image management solutions, are announcing a new partnership in digital pathology. Through the partnership, Qritive's artificial intelligence modules and Corista's DP3® image management platform will be integrated to help pathologist's focus their...
Everest Medicines Announces Partner Calliditas Therapeutics Reports Positive Topline Results from Phase 3 NefIgArd Trial Evaluating Nefecon in IgA Nephropathy
SHANGHAI, March 14, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company") announced today that its partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") reported positive topline results from the global, randomized, double-blind, placebo-controlled Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon versus placebo in patients with primary IgA nephropathy (IgAN). The...
AnnJi Pharmaceutical Announced Licensing Agreement With Avenue Therapeutics To Develop And Commercialize AJ201, A First-In-Class Clinical Asset For The Kennedy’s Disease Treatment
TAIPEI, March 14, 2023 /PRNewswire/ -- AnnJi Pharmaceutical Co. (AnnJi) has entered into an exclusive license agreement with Avenue Therapeutics Inc. (Avenue, NASDAQ: ATXI) for the development and commercialization of AJ201 in the U.S., Canada, European Union, Great Britain, and Israel for spinal and bulbar muscular atrophy (SBMA), also known as Kennedy's Disease. Under the terms of the license...
Telix’s ZIRCON Phase III Kidney Cancer Imaging Study Presented in “Game Changing” Session at EAU
MELBOURNE, Australia, March 14, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces additional positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118).1 The results were featured in a "Game Changing" oral session delivered...
